Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Phase 1 Completed 24 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.

Timeline

Start: 2007-02
Primary completion: 2008-09
Completion: 2008-09

Publications

Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012 Sep;52(9):1388-98. doi: 10.1177/0091270011415526. Epub 2011 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ticagrelor	Small molecule	180 mg	Oral

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Summary

Timeline

Publications

Drugs

Indications